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Coronary arteriography and biplane ventriculography
were performed in 51 patients during the acute (mean
of 6.6 hours after onset of symptoms) and chronic (1 to
3 months after admission) phase of myocardial infarc-
tion. Twenty-four patients were treated in a conventional
manner. In 27 patients, reperfusion was achieved with
intracoronary streptokinase after 24 ± 20 minutes of
infusion. Peak creatine kinase and cumulative creatine
kinase release were derived from serial creatine kinase
measurements. Ejection fraction and the length of the
akinetic or dyskinetic segments were calculated in the
chronic phase.
The time interval between onset of symptoms and
peak creatine kinase was significantly shorter for the
streptokinase-treated patients as compared with the con-
ventionally treated patients (13.5 ± 5.3 versus 22.9 ±
7.4 hours, p = 0.0001). Significant linear correlations
were obtained for both streptokinase-treated and control
Shell and Sobel (1,2) developed a model for calculating
infarct size using serial measurements of serum creatine
kinase activity. Subsequent studies (3-9), however, sug-
gested that different subsets of patients with myocardial
infarction have diferent patterns of enzyme release.
This study describes the kinetics of creatine kinase re-
lease in patients who had successful reperfusion after re-
ceiving intracoronary streptokinase therapy during acute
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patients, relating: 1) peak creatine kinase value to both
length of the noncontracting segment and ejection frac-
tion in the chronic phase, and 2) cumulative creatine
kinase release to both length of the noncontracting seg-
ment and ejection fraction in the chronic phase. Patients
treated with streptokinase experienced a relatively greater
release of enzyme for a given infarct size as compared
with those treated in a conventional manner. The dif-
ference in enzyme release between the two groups in-
creased as infarct size increased.
These observations may be explained by enhanced
washout of enzyme from the infarct zone, secondary to
reperfusion after intracoronary streptokinase therapy.
The variability in crelltine kinase release observed in the
streptokinase-treated patients with small infarcts sug-
gests that prediction of infarct size for an individual
patient from time-activity curves of creatine kinase re-
lease should be made with caution.
myocardial infarction. The pattern of creatine kinase release
in the patients receiving streptokinase therapy was compared
with that of patients given conventional therapy. An attempt
was made to define the relation between creatine kinase
release and angiographic estimates of infarct size for both
groups of patients.
Methods
Patients
Streptokinase group. Twenty-seven of 67 consecutive
patients admitted with acute myocardial infarction, in whom
the infarct vessel was recanalized by intracoronary strep-
tokinase therapy, were included in this study. All 27 patients
fulfilled the following criteria: I) informed consenr for car-
diac catheterization and administration of intracoronary
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medication was obtained; 2) the time from onset of chest
pain to hospital admission was less than 24 hours in duration;
3) total occlusion of the infarct-related vessel was present
at the time of initial angiographic visualization; 4) at the
end of the streptokinase infusion there was prompt antegrade
filling of the initially occluded vessel; 5) angiography was
repeated during the chronic stage of infarction; 6) no surgical
intervention was made between the initial angiogram and
the repeat study; and 7) serial blood samples for creatine
kinase assay were drawn. The remaining 40 patients were
excluded from this analysis on the basis of the following
exclusion criteria: 1) history of previous myocardial infarc-
tion; 2) cardiogenic shock; 3) recent intramuscular injection;
4) intraaortic balloon counterpulsation; 5) clinical signs of
infarct extension or recurrent infarction during the study
period; 6) demonstration of reocclusion of the infarct vessel
at repeat angiography, in the chronic stage; and 7) inade-
quate number of blood samples drawn for serial creatine
kinase analysis.
Comparison group. These patients were selected from
66 consecutive patients presenting with acute myocardial
infarction who underwent initial angiography as part of a
protocol undertaken before the advent of streptokinase ther-
apy. No attempt was made to reopen the infarct vessel with
a guidewire or intracoronary administration of drugs. Twenty-
four of these 66 patients who met the same criteria as the
streptokinase group formed the comparison group.
Study Protocol
Diagnosis of acute myocardial infarction. The diag-
nosis of acute myocardial infarction was determined on the
basis of a history of chest pain lasting more than 30 minutes,
and associated with electrocardiographic changes suggestive
of acute ischemia in at least two leads (ST segment elevation
or depression of at least 0.1 mV, loss of R waves or de-
velopment of new Q waves, or both). The diagnosis was
confirmed retrospectively in all patients by an increase of
creatine kinase to at least twice the upper limit of normal.
The onset of chest pain was determined by the same observer
for all patients in both groups.
Coronary reperfusion technique. The method of initial
angiography during the acute phase of an acute myocardial
infarction and administration of intracoronary streptokinase
has been described previously (10). Reperfusion was achieved
by intracoronary streptokinase infusion (2,000 units/min)
alone in 21 patients and combined with guidewire reca-
nalization in 6 patients. Reperfusion was observed after 24
± 20 (mean ± standard deviation) minutes of therapy in
the group as a whole. A mean of 6.9 ± 6.3 hours elapsed
between the onset of chest pain and recanalization. The total
duration of streptokinase infusion was 64 ± 26 minutes.
Assessment of left ventricular function and infarct
size. All patients in both groups underwent biplane left
ventriculography before coronary arteriography during the
acute and chronic stages of infarction. Ventricular volumes
were calculated using the area-length formula of Dodge et
al. (11). On the basis of systolic and diastolic ventricular
volume measurements, ejection fraction in the acute and
chronic stages was calculated, The length of any akinetic
or dyskinetic segment was measured in centimeters using
the method of Feild et al. (12). The severity of an intra-
luminal coronary artery narrowing was assessed using the
criteria of Gensini (13).
Creatine kinase determination. Blood for creatine ki-
nase assay was drawn immediately on admission, before
any intervention and every 2 to 3 hours thereafter for at
least 48 hours. Creatine kinase activity was assayed by the
technique of Szasz et al. (14). Time-activity curves were
constructed for each patient. From these curves peak crea-
tine kinase activity was measured. Total creatine kinase
release was calculated according to the method of Norris et
al. (3).
Differences between study and control groups (Table
1). The two groups were comparable in age, sex, duration
of symptoms before initial angiography, localization of in-
farct vessel, extent of coronary artery disease, presence of
collateral circulation, initial ejection fraction and the initial
length of noncontracting segments. Both groups of patients
received intravenous nitroglycerin for at least 48 hours. The
duration of symptoms from onset of chest pain to initial
angiography in the streptokinase group and the control group
was 5.9 ± 6.3 and 7.4 ± 4,5 hours, respectively (prob-
ability [p] = not significant [NS]).
The groups differed in the following variables: 1) the
initial creatine kinase values for the comparison group were
slightly higher than those of the streptokinase group (179
± 170 versus 100 ± 79 U/liters [p = 0.05]); 2) only
patients in the streptokinase group received prednisolone,
747 mg intravenously; aspirin, 1 g intravenously and ni-
fedipine, 10 mg sublingually; 3) all patients in the strepto-
kinase group received at least 72 hours of a continuous
intravenous infusion of heparin of 20,000 or more U/day
followed by oral coumadin. Twenty patients in the com-
parison group received a continuous infusion of heparin, 12
of whom remained on oral coumadin therapy while 4 pa-
tients received subcutaneous heparin, 20,000 U/day, until
they began to walk; 4) repeat angiography was performed
at a later date in the control group than in the streptokinase
group (63 ± 45 versus 33 ± 54 days, respectively [p <
0.05]).
In the streptokinase group of 27 patients, angiography
during the chronic stage revealed 18 patients with a 90%
or greater residual stenosis, and 9 patients with a less than
90% residual stenosis in the infarct vessel. Ten of the 24
patients in the comparison group demonstrated spontaneous
recanalization of the infarct vessel at repeat angiography
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*Denotes that the difference between the two groups is statistically
significant (p < 0.05). t Normal ejection fraction using biplane ventric-
ulography is > 60%. CAD '= coronary artery disease; CK '= creatine
kinase; LAD '= left anterior descending coronary artery; LCx '= left
circumflex coronary artery; RCA '= right coronary artery.
during the chronic stage, Of these 10 patients, 6 had a greater
than 90% residual stenosis.
Statistics. Data are presented as mean values ± stan-
dard deviation. The t test, paired t test and chi-square test
were used to compare variables. A probability value of 0.05
or less was considered significant. Linear correlations and
inverse regression techniques were used.
Table 1. Clinical and Angiographic Data
Sex
Male
Female
Age (yr)
Duration of symptoms
prior to
angiography (hours)
CK on admission
(U/L)
Infarct vessel
LAD
LCx
RCA
Patients with
collateral channels
to the infarct (no.)
Extent of CAD
I vessel disease
2 vessel disease
3 vessel disease
Time from initial to
repeat angiography
(days)
Ejection fraction
Initialt
Chronic
Noncontracting segment
Initial (em)
Chronic
Streptokinase
Group
(n '= 27 patients)
24
3
55
5.9 ± 6.3
100 ± 79
13
4
10
13
14
6
7
33 ± 54
54 ± II
62 ± 9
7.1 ± 6.5
2.2 ± 4.0
Control Group
(n '= 24 patients)
21
3
54
7.4 ± 4.5
179 ± 170*
II
7
6
12
8
10
6
63 ± 55*
52 ± 10
48 ± 14*
9.0 ± 5.0
8.8 ± 6.9*
NS). The time elapsed between onset of symptoms and peak
creatine kinase levels was significantly shorter for the strep-
tokinase group (13.5 ± 5.3 versus 22,9 ± 7.4 hours [p =
0.0001]). In the streptokinase group peak creatine kinase
was reached 6.5 ± 4.5 hours after recanalization. Total
creatine kinase release was lower in the streptokinase group
than in the comparison group but the difference did not
reach statistical significance (1.058 ± 963 U/liter versus
1,571 ± 963 U/liter [p = NS]).
There were no significant differences with respect to in-
farct size or enzyme release between the 10 patients in the
comparison group who demonstrated spontaneous recanal-
ization and those with persistent occlusion.
Changes in left ventricular function and infarct size
(Fig. 2 to 4). In the acute stage before any interventions,
the ejection fraction and the length of the noncontracting
segments of patients in the streptokinase group were com-
parable with those of the comparison group. However, the
ejection fraction and the length of the noncontracting seg-
ments improved between acute and chronic angiography in
the streptokinase group but not in the comparison group.
Angiography in the chronic phase revealed significantly bet-
ter function in the streptokinase group than in the conven-
tionally treated group.
Correlation of peak creatine kinase and cumulative
creatine kinase release with length of noncontracting
segments and ejection fraction in the chronic stage. There
was a significant linear correlation between peak creatine
kinase and length of the noncontracting segment in both
groups of patients. However, the slope of the regression
line was significantly steeper for the streptokinase-treated
patients (169 versus 44, p = 0.000l) (Fig. 2). In addition,
there was a significant correlation between peak creatine
kinase and ejection fraction in both groups of patients. The
slope of this regression line was significantly steeper for the
streptokinase group ( - 65 versus - 28, P = 0.000l) (Fig.
3).
There was a significant linear correlation between total
creatine kinase release and the length of the noncontracting
Figure 1. Time in hours from onset of symptoms to peak creatine
kinase release (CK-Max). SD = standard deviation; SK =
streptokinase.
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Results
There was a significant correlation between peak creatine
kinase activity and cumulative kinase release in both groups
of patients: streptokinase group, r = 0.97 and comparison
group, r = 0.89, p = 0.0001.
Creatine kinase kinetics (Fig. 1). Peak creatine kinase
activity was 766 ± 798 U/liter in the streptokinase group
and 1,043 ± 538 U/liter in the comparison group (p =
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Figure 2. Correlation between peak creatine kinase
(CK-Max) and the length of the noncontracting seg-
ment in the chronic stage (AKSc) in the strepto-
kinase group (left) and the control group (right).
Dotted lines represent the 95% confidence intervals.
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segment in the streptokinase group and the comparison group.
The slope of this line was significantly steeper for the strep-
tokinase group (199 versus 85, p = 0.004) (Fig. 4). A
significant correlation was also observed between cumula-
tive creatine kinase release and ejection fraction in both
groups. This line was steeper for the streptokinase group
but the difference did not reach statistical significance ( - 73
versus -45, p = NS) (Fig. 5).
Discussion
Earlier time to peak creatine kinase activity. Previous
studies using creatine kinase time-activity curves in patients
with acute myocardial infarction (2,3) indicated that the
average time from the onset of symptoms to peak creatine
kinase activity varies from 16 to 30 hours. The data from
our control group is in agreement with these studies.
In contrast, our patients with successful reperfusion after
intracoronary administration of streptokinase demonstrated
a significantly shorter time to peak creatine kinase activity
of 13.5 hours. This finding, in human subjects, is in agree-
ment with previous animal experiments that showed earlier
times to peak creatine kinase after reperfusion after tem-
porary coronary artery ligation (5,15). Recent reports (16--30)
in human subjects also indicate that early recanalization
during acute myocardial infarction results in an earlier time
to peak creatine kinase (10 to 14 hours). Investigators in a
randomized cooperative study using intravenous streptoki-
nase observed a mean time of 15.7 hours to peak creatine
kinase in patients who received therapy less than 3 hours
after the onset of symptoms (21). This contrasts with a mean
time of 20.8 hours to peak creatine kinase in their patients
who received intravenous streptokinase therapy after 3 hours.
Although they did not have angiographic correlations it is
conceivable that the early institution of therapy resulted in
the reopening of the infarct vessel in a fraction of the patients
they studied.
It is conceivable that spontaneous recanalization, which
occurred in 10 of the 24 control patients at some time be-
tween initial and repeat angiography, may have diminished
the differences between our conventionally treated group
and the streptokinase-treated group. However, comparison
of the pattern ofenzyme release in our conventionally treated
patients with spontaneous recanalization with that in patients
with persistent occlusion revealed no significant differences.
Increased creatine kinase release. The data derived
from our study suggest that for infarcts of equal size, as
assessed by length of akinetic or dyskinetic segment, there
is a greater peak creatine kinase and total creatine kinase
release in the patients treated with recanalization than in the
conventionally treated group. This is in agreement with
previous experimental work by Vatner et al. (5), who ob-
served that for infarcts of equal size as measured at autopsy
there was a relatively greater release of creatine kinase into
the serum in dogs with reperfusion than in the dogs with
permanent coronary occlusion. Schuster et al. (22) corre-
lated infarct size, as measured pathologically, with creatine
kinase release in human beings and observed a relatively
greater release of creatine kinase for similar-sized infarcts
in patients who demonstrated hemorrhagic necrosis. Hem-
orrhagic necrosis was presumed to be a marker of reper-
fusion. As suggested by previous investigators (5), a pos-
sible explanation for these observations of 1) an earlier time
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Figure 3. Correlation between peak crea-
tine kinase (CK-Max) and the ejection frac-
tion in the chronic stage (EFc) in the strep-
tokinase group (left) and in the control group
(right). Dotted lines represent the 95%
confidence intervals.
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(right). Dotted lines represent the 95% confidence
intervals,
to peak creatine kinase activity, and 2) a greater cumulative
release of creatine kinase for infarcts of equal size is that
there is a washout effect resulting from reperfusion,
The original formula of Sobel and colleagues (2) for
estimating infarct size from time-activity curves of creatine
kinase release assumed a constant serum entry ratio of crea-
tine kinase into the peripheral circulation irrespective of the
size of the infarction or the presence of collateral blood
flow, Experimental studies by Cairns et al. (7) comparing
multiple small infarcts with a single large infarct in a dog
model demonstrated variable serum entry of creatine kinase
depending on the size of the infarct. Swain et al. (8), also
using a dog model, suggested that larger infarcts, which
have a large central zone of severely reduced regional blood
flow, will release disproportionately less enzyme into the
peripheral circulation.
Patients with a large infarct in whom reperfusion is achieved
should, theoretically, have an improved blood flow to the
central ischemic zone, unless there is a "no reflow" phe-
nomenon. Our finding that the difference in enzyme release
between patients treated with reperfusion and conventionally
treated patients increases with increasing infarct size sug-
gests that: I) a no reflow phenomenon did not occur in our
patients with reperfusion, and 2) in patients without reper-
fusion the serum entry ratio of creatine kinase into the pe-
ripheral circulation is inversely related to infarct size.
Our study demonstrated some degree of variability in the
values for peak creatine kinase and cumulative creatine ki-
nase release for patient in the streptokinase group with a
small infarct. A possible explanation for the increased var-
iability may be that determination of extent of tissue damage
based on length of noncontracting segment may be less
accurate in patients with a small infarct.
Limitations of the study. This study was retrospective
and nonrandomized and therefore subject to several limi-
tations. Only patients in the streptokinase group received
prednisolone, aspirin and nifedipine. However, a recent
controlled study by Madias and Hood (23) found no sig-
nificant difference in peak creatine kinase between patients
who received corticosteroids as compared with a control
group. In addition, we are not aware of any direct effect of
aspirin and nifedipine on creatine kinase release other than
their possible role in preserving the patency of the coronary
artery after streptokinase infusion, Patients in our compar-
ison group had repeat angiography at a later time than those
in the streptokinase group. It is not likely that the delay in
evaluation of ejection fraction in the chronic stage in our
comparison group would have exaggerated the difference
in angiographic estimates of infarct size. Borer et al. (24)
observed a slight improvement in ejection fraction in pa-
tients during the chronic phase of myocardial infarction.
Our comparison group had a higher initial creatine kinase
value. This initial elevation in some of our conventionally
treated patients did not preclude calculation of peak creatine
kinase or cumulative creatine kinase release. It is possible
that our correlations may have been improved had the more
specific marker creatine kinase-MB been used. However,
none of our patients received intramuscular injections or
underwent defibrillation.
Clinical implications. Patients in whom successful re-
canalization is achieved by intracoronary streptokinase ther-
apy during acute myocardial infarction have an earlier rise
to peak creatine kinase activity and a relatively greater cu-
mulative release of creatine kinase as compared with con-
ventionally treated patients with an infarct of similar size.
It is possible that the pattern of early enzyme release may
Figure 5. Correlation between cumulative
creatine kinase release (CK-Rel) and the
ejection fraction in the chronic stage (EFc)
in the streptokinase group (left), and the
control group (right). Dotted lines repre-
sent the 95% confidence intervals.
y"3715-45(x)
,"-0.63 ""24. .
Y" 5630-73(x)
,"-0.69 ""27
E 5000
" --2. 4000 '-'"
q; '",
~ 3000 '-'", .'__
~ -- ~"-_. ---,-
u 2000 ------------- __~.". :.-----~~?:--.-~~~------i.-.---.-------
1000 ----.:-:;;:::'- __ ....• ........ --e-
O 30 36 42 48 54· 6~ ·:66' '72 78 30 36
EFe (%)
680 BLANKE ET AL.
CK RELEASE AFTER REPERFUSION
lACC Vol. 3, No.3
March 1984:675-80
be used as a noninvasive marker for early coronary reca-
nalization (25). In spite of a relatively large cumulative
release of enzyme, patients experiencing early recanaliza-
tion may have a better prognosis. The variability in creatine
kinase release observed in our streptokinase-treated patients
with a small infarct suggests that prediction of infarct size
for an individual patient from time-activity curves of crea-
tine kinase release should be made with caution.
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